Now showing items 1728-1747 of 4516

    • Genomic Evolution of Breast Cancer Metastasis and Relapse. 

      Yates, LR; Knappskog, S; Wedge, D; Farmery, JHR; Gonzalez, S; Martincorena, I; Alexandrov, LB; Van Loo, P; Haugland, HK; Lilleng, PK; Gundem, G; Gerstung, M; Pappaemmanuil, E; Gazinska, P; Bhosle, SG; Jones, D; Raine, K; Mudie, L; Latimer, C; Sawyer, E; Desmedt, C; Sotiriou, C; Stratton, MR; Sieuwerts, AM; Lynch, AG; Martens, JW; Richardson, AL; Tutt, A; Lønning, PE; Campbell, PJ (2017-08)
      Patterns of genomic evolution between primary and metastatic breast cancer have not been studied in large numbers, despite patients with metastatic breast cancer having dismal survival. We sequenced whole genomes or a panel ...
    • Genomic gain and over expression of CCL2 correlate with vascular invasion in stage I non-seminomatous testicular germ-cell tumours. 

      Gilbert, DC; Chandler, I; Summersgill, B; McIntyre, A; Missiaglia, E; Goddard, NC; Huddart, RA; Shipley, J (2011-08)
      Testicular germ-cell tumours (TGCT) are the most frequent solid tumour to affect young Caucasian adult males and have increased in incidence over recent decades. In clinical stage I non-seminomas, (NSGCT) histological ...
    • Genomic Instability and <i>TP53</i> Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment. 

      Schuster, EF; Gellert, P; Segal, CV; López-Knowles, E; Buus, R; Cheang, MCU; Morden, J; Robertson, J; Bliss, JM; Smith, I; Dowsett, M; POETIC Trial Management Group and Trialists (2019-01)
      <h4>Purpose</h4>Although aromatase inhibitor (AI) treatment is effective in estrogen receptor-positive postmenopausal breast cancer, resistance is common and incompletely explained. Genomic instability, as measured by ...
    • Genomic instability and the selection of treatments for cancer. 

      Martin, SA; Hewish, M; Lord, CJ; Ashworth, A (2010-01)
      A critical link exists between DNA mutation and chromosomal rearrangements (genomic instability) and cancer development. This genomic instability can manifest itself as small changes at the nucleotide level or as gross ...
    • The genomic landscape of plasma cells in systemic light chain amyloidosis. 

      Boyle, EM; Ashby, C; Wardell, CP; Rowczenio, D; Sachchithanantham, S; Wang, Y; Johnson, SK; Bauer, MA; Weinhold, N; Kaiser, MF; Johnson, DC; Jones, JR; Pawlyn, C; Proszek, P; Schinke, C; Facon, T; Dumontet, C; Davies, FE; Morgan, GJ; Walker, BA; Wechalekar, AD (2018-12)
    • Genomic landscape of platinum resistant and sensitive testicular cancers. 

      Loveday, C; Litchfield, K; Proszek, PZ; Cornish, AJ; Santo, F; Levy, M; Macintyre, G; Holryod, A; Broderick, P; Dudakia, D; Benton, B; Bakir, MA; Hiley, C; Grist, E; Swanton, C; Huddart, R; Powles, T; Chowdhury, S; Shipley, J; O'Connor, S; Brenton, JD; Reid, A; de Castro, DG; Houlston, RS; Turnbull, C (2020-05-04)
      While most testicular germ cell tumours (TGCTs) exhibit exquisite sensitivity to platinum chemotherapy, ~10% are platinum resistant. To gain insight into the underlying mechanisms, we undertake whole exome sequencing and ...
    • The genomic landscape of testicular germ cell tumours: from susceptibility to treatment. 

      Litchfield, K; Levy, M; Huddart, RA; Shipley, J; Turnbull, C (2016-07)
      The genomic landscape of testicular germ cell tumour (TGCT) can be summarized using four overarching hypotheses. Firstly, TGCT risk is dominated by inherited genetic factors, which determine nearly half of all disease risk ...
    • Genomic loss of heterozygosity and survival in the REAL3 trial. 

      Smyth, EC; Cafferkey, C; Loehr, A; Waddell, T; Begum, R; Peckitt, C; Harding, TC; Nguyen, M; Okines, AF; Raponi, M; Rao, S; Watkins, D; Starling, N; Middleton, GW; Wadsley, J; Mansoor, W; Crosby, T; Wotherspoon, A; Chau, I; Cunningham, D (2018-11-30)
      <h4>Background</h4>Homologous recombination deficiency (HRD) measured using a genomic signature for loss of heterozygosity (LOH) predicts benefit from rucaparib in ovarian cancer. We hypothesized that some oesophagogastric ...
    • Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). 

      Barry, GS; Cheang, MC; Chang, HL; Kennecke, HF (2016-04)
      A prospective study was conducted to identify biomarkers associated with resistance to panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Patients with previously treated, codon 12/13 KRAS wt, ...
    • GENOMIC MEDICINE Genomics and the Continuum of Cancer Care 

      Stratton, M (MASSACHUSETTS MEDICAL SOC, 2011-01)
    • Genomic profile of advanced breast cancer in circulating tumour DNA. 

      Kingston, B; Cutts, RJ; Bye, H; Beaney, M; Walsh-Crestani, G; Hrebien, S; Swift, C; Kilburn, LS; Kernaghan, S; Moretti, L; Wilkinson, K; Wardley, AM; Macpherson, IR; Baird, RD; Roylance, R; Reis-Filho, JS; Hubank, M; Faull, I; Banks, KC; Lanman, RB; Garcia-Murillas, I; Bliss, JM; Ring, A; Turner, NC (2021-04-23)
      The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical and temporal heterogeneity. Here we use plasma circulating ...
    • Genomics of lethal prostate cancer at diagnosis and castration resistance. 

      Mateo, J; Seed, G; Bertan, C; Rescigno, P; Dolling, D; Figueiredo, I; Miranda, S; Nava Rodrigues, D; Gurel, B; Clarke, M; Atkin, M; Chandler, R; Messina, C; Sumanasuriya, S; Bianchini, D; Barrero, M; Petermolo, A; Zafeiriou, Z; Fontes, M; Perez-Lopez, R; Tunariu, N; Fulton, B; Jones, R; McGovern, U; Ralph, C; Varughese, M; Parikh, O; Jain, S; Elliott, T; Sandhu, S; Porta, N; Hall, E; Yuan, W; Carreira, S; de Bono, JS (2020-04)
      The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, ...
    • Genomics, bio specimens, and other biological data: Current status and future directions. 

      Rosenstein, BS; Rao, A; Moran, JM; Spratt, DE; Mendonca, MS; Al-Lazikani, B; Mayo, CS; Speers, C (2018-10)
    • Genotoxicity of human breast milk from different countries 

      Martin, FL; Cole, KJ; Weaver, G; Hong, GS; Lam, BC; Balaram, P; Grover, PL; Phillips, DH (OXFORD UNIV PRESS, 2001-09)
      Dietary and/or environmental factors appear to play a key role in the international variations that exist in breast cancer incidence. The genotoxicity of breast milk extracts is being examined as a possible indicator of ...
    • Genotoxins and the initiation of sporadic breast cancer 

      Martin, FL (2001-03)
      Breast cancer is the most frequently diagnosed female malignancy world-wide. The aetiology of the majority of cases remains obscure and the only genotoxin as yet known to initiate breast cancer is ionizing radiation, High ...
    • Geometric and dosimetric evaluation of the differences between rigid and deformable registration to assess interfraction motion during pelvic radiotherapy. 

      White, I; McQuaid, D; McNair, H; Dunlop, A; Court, S; Hopkins, N; Thomas, K; Dearnaley, D; Bhide, S; Lalondrelle, S (2019-01)
      <h4>Background and purpose</h4>Appropriate internal margins are essential to avoid a geographical miss in intensity-modulated radiation therapy (IMRT) for endometrial cancer (EC). This study evaluated interfraction target ...
    • Geometric and dosimetric evaluations of atlas-based segmentation methods of MR images in the head and neck region. 

      Kieselmann, JP; Kamerling, CP; Burgos, N; Menten, MJ; Fuller, CD; Nill, S; Cardoso, MJ; Oelfke, U (2018-07-11)
      Owing to its excellent soft-tissue contrast, magnetic resonance (MR) imaging has found an increased application in radiation therapy (RT). By harnessing these properties for treatment planning, automated segmentation methods ...
    • Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia. 

      Speedy, HE; Kinnersley, B; Chubb, D; Broderick, P; Law, PJ; Litchfield, K; Jayne, S; Dyer, MJS; Dearden, C; Follows, GA; Catovsky, D; Houlston, RS (2016-11)
      Chronic lymphocytic leukemia (CLL) can be familial; however, thus far no rare germ line disruptive alleles for CLL have been identified. We performed whole-exome sequencing of 66 CLL families, identifying 4 families where ...
    • Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression, and drug response. 

      Zhang, P; Kitchen-Smith, I; Xiong, L; Stracquadanio, G; Brown, K; Richter, PH; Wallace, MD; Bond, E; Sahgal, N; Moore, S; Nornes, S; De Val, S; Surakhy, M; Sims, D; Wang, X; Bell, DA; Zeron-Medina, J; Jiang, Y; Ryan, AJ; Selfe, JL; Shipley, J; Kar, S; Pharoah, PDP; Loveday, C; Jansen, R; Grochola, LF; Palles, C; Protheroe, A; Millar, V; Ebner, DV; Pagadala, M; Blagden, SP; Maughan, TS; Domingo, E; Tomlinson, I; Turnbull, C; Carter, H; Bond, GL (2021-02-08)
      Insights into oncogenesis derived from cancer susceptibility loci (single nucleotide polymorphisms, SNP) hold the potential to facilitate better cancer management and treatment through precision oncology. However, therapeutic ...
    • Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. 

      Copson, ER; Maishman, TC; Tapper, WJ; Cutress, RI; Greville-Heygate, S; Altman, DG; Eccles, B; Gerty, S; Durcan, LT; Jones, L; Evans, DG; Thompson, AM; Pharoah, P; Easton, DF; Dunning, AM; Hanby, A; Lakhani, S; Eeles, R; Gilbert, FJ; Hamed, H; Hodgson, S; Simmonds, P; Stanton, L; Eccles, DM (2018-02)
      <h4>Background</h4>Retrospective studies provide conflicting interpretations of the effect of inherited genetic factors on the prognosis of patients with breast cancer. The primary aim of this study was to determine the ...